Journal
RHEUMATOLOGY
Volume 56, Issue 11, Pages 2004-2014Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/kex315
Keywords
TNF; RA; biologics; tapering; interruption treatment; flare
Categories
Funding
- Arthritis Research UK [18813]
- MRC [MC_UU_12023/14, G1001516] Funding Source: UKRI
- Medical Research Council [MC_U122886349, MC_UU_12023/14, G1001516] Funding Source: researchfish
- Versus Arthritis [18813] Funding Source: researchfish
Ask authors/readers for more resources
Objectives. RA patients receiving TNF inhibitors (TNFi) usually maintain their initial doses. The aim of the Optimizing Treatment with Tumour Necrosis Factor Inhibitors in Rheumatoid Arthritis trial was to evaluate whether tapering TNFi doses causes loss of clinical response. Methods. We enrolled RA patients receiving etanercept or adalimumab and a DMARD with DAS28 under 3.2 for over 3 months. Initially (months 0-6) patients were randomized to control (constant TNFi) or two experimental groups (tapering TNFi by 33 or 66%). Subsequently (months 6-12) control subjects were randomized to taper TNFi by 33 or 66%. Disease flares (DAS28 increasing >= 0.6 with at least one additional swollen joint) were the primary outcome. Results. Two hundred and forty-four patients were screened, 103 randomized and 97 treated. In months 0-6 there were 8/50 (16%) flares in controls, 3/26 (12%) with 33% tapering and 6/21 (29%) with 66% tapering. Multivariate Cox analysis showed time to flare was unchanged with 33% tapering but was reduced with 66% tapering compared with controls (adjusted hazard ratio 2.81, 95% CI: 0.99, 7.94; P = 0.051). Analysing all tapered patients after controls were re-randomized (months 6-12) showed differences between groups: there were 6/48 (13%) flares with 33% tapering and 14/39 (36%) with 66% tapering. Multivariate Cox analysis showed 66% tapering reduced time to flare (adjusted hazard ratio 3.47, 95% CI: 1.26, 9.58; P = 0.016). Conclusion. Tapering TNFi by 33% has no impact on disease flares and appears practical in patients in sustained remission and low disease activity states.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available